Asia-Pacific Gene Therapy Market to Reach US$ 14.59 Billion by 2033 | Major Players - AnGes MG, Inc, MediPost, Transcell Biologics

Asia-Pacific gene therapy market size reached US$ 1.06 Billion in 2024 and is expected to reach US$ 14.59 Billion by 2033, growing at a CAGR of 34.1% during the forecast period 2025-2033.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/asia-pacific-gene-therapy-market?kb

United States: Recent Industry Developments

✅ Jan 2026: FDA approvals expanded for next-generation gene therapies targeting rare genetic and neuromuscular disorders.

✅ December 2026: Biotech companies scaled up viral vector manufacturing to support late-stage gene therapy pipelines.

✅ November 2025: Major U.S. pharma players advanced CRISPR-based gene editing therapies into Phase III clinical trials.

Asia-Pacific: Recent Industry Developments

✅ Jan 2026: Japan accelerated regulatory pathways for regenerative and gene therapies under its fast-track approval framework.

✅ December 2026: China increased investments in domestic gene therapy R&D, focusing on oncology and inherited diseases.

✅ November 2025: South Korea and Singapore strengthened public-private partnerships to expand clinical gene therapy research and manufacturing capacity.

List of Top Key Player:

Thermo Fisher Scientific Inc., Genepeutic Bio, Biosyngen, Wuxiapptec, Esco Aster, CytoMed Therapeutics, PHARMICELL Co., Ltd, AnGes MG, Inc, MediPost, Transcell Biologics

Industry Developments:

Jan 2026
• Asia-Pacific gene therapy pipelines expanded as regional regulators accelerated review pathways for rare and genetic disease treatments.

Dec 2025
• Increased cross-border collaborations between APAC biotech firms and global pharma players boosted local manufacturing and technology transfer.

Nov 2025
• Rising investments in viral vector production facilities strengthened Asia-Pacific's position in scalable gene therapy development.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=asia-pacific-gene-therapy-market?kb

Forecast Projection:

The Asia-Pacific Gene Therapy Market is poised for significant growth between 2025 and 2032. In 2024, the market maintained a steady upward trajectory, and with strategic initiatives by leading players accelerating adoption, the market is expected to soar throughout the forecast period. Companies leveraging these trends are well-positioned to capture emerging opportunities and maximize revenue potential.

Market Key Segmentations:

🔹 By Vector Type
• Viral vectors dominate (70% share), led by strong clinical success and regulatory acceptance of AAV and lentiviral platforms across APAC.

• Adeno-Associated Virus (AAV) holds the largest sub-share, driven by safety profile and rising rare disease trials in China, Japan, and South Korea.

• Non-viral vectors (20% share) are fast-growing, supported by cost efficiency and scalability for next-gen gene delivery.

🔹 By Technique
• Gene addition leads the market (45% share), widely used in blood disorders and inherited diseases with established clinical pathways.

• Gene editing (30% share) is the fastest-growing, fueled by CRISPR-based research investments and precision medicine initiatives.

• Gene replacement remains relevant (25% share), particularly in monogenic rare disease therapies.

🔹 By Application
• Oncology accounts for the largest share (40%), driven by CAR-T adoption and expanding cancer gene therapy pipelines in APAC.

• Rare diseases (30% share) see strong momentum, supported by orphan drug incentives and early diagnosis programs.

• Blood disorders (20% share) continue steady growth, led by therapies targeting thalassemia and hemophilia.

Regional Growth Analysis:

⇥ Asia-Pacific - 55%
Holds the larger share driven by rising clinical trials, government funding, and expanding biotech ecosystems in China, Japan, and South Korea.

⇥ North America - 45%
Maintains a strong presence through technology transfers, partnerships, and commercialization of advanced gene therapy platforms.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/asia-pacific-gene-therapy-market?kb

Asia-Pacific Gene Therapy Market - Real M&A & Strategic Activity (Latest)

✦ Asia-focused biotech CDMO Novotech secures new investment from GIC, Temasek and TPG Asia to accelerate growth and pursue transformative M&A opportunities in gene therapy and biopharma services.

✦ Cell Therapies (Australia) and ENCell (South Korea) sign a strategic APAC partnership to expand cell & gene therapy manufacturing across the region.
✦ Cell Therapies and Teijin (Japan) agree MoU to strengthen regional infrastructure for advanced cell & gene therapies across Japan & APAC.

✦ Strategic licensing and partnership deals in the region boost access to gene therapies, including out-licensing and co-development agreements reported across APAC markets.

✦ Bharat Biotech launches a new cell & gene therapies arm (Nucelion Therapeutics), signaling diversification and expansion in India's gene therapy ecosystem.

Request 2 Days Free Trials with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?kb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?kb

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.